Tlajomulco De Zuniga

Researchers are evaluating the safety and effectiveness of tulisokibart, a humanized monoclonal antibody, in people with moderately to severely active Crohn's disease. The research includes two studies: Study 1, which has induction and maintenance treatment phases, and Study 2, which only includes induction treatment. The main goals are to see if tulisokibart can help participants achieve clinical remission and endoscopic response compared to placebo, measured at 12 and 52 weeks depending on the study and region (US/FDA or EU/EMA).

Researchers are evaluating the effectiveness and safety of RO7837195 in adults with moderately to severely active ulcerative colitis who have not responded well or tolerated conventional or advanced treatments. This Phase IIb study aims to compare RO7837195 to a placebo during the initial treatment phase and then monitor all participants receiving the active drug to assess clinical remission at 12 weeks. The study includes a screening period lasting up to 5 weeks, followed by a 12-week induction phase where participants receive either RO7837195 or a matching placebo according to a specified schedule. After this induction phase, all participants enter a 40-week active treatment extension where they receive RO7837195 regardless of their earlier response. A safety follow-up period occurs after the last dose to continue monitoring participant health. Participants will undergo assessments throughout the study to measure clinical remission at week 12 and to monitor safety and pharmacokinetics. Researchers will collect data on symptoms, treatment effects, and any side effects experienced. The total participation involves multiple phases designed to carefully evaluate the long-term impact and safety of RO7837195 in ulcerative colitis management.

Researchers are investigating the effects of a medicine called BI 690517 in combination with empagliflozin for adults with chronic kidney disease who are at risk of their condition worsening. This study includes people both with and without type 2 diabetes and those already taking certain kidney-related medicines like ACE inhibitors or angiotensin receptor blockers. The goal is to understand if adding BI 690517 helps protect kidney function and reduces risks related to kidney failure and heart problems. This is a Phase 3 clinical trial conducted over about 3 to 4 years. The study has two parts. First, participants receive either empagliflozin or a placebo similar to BI 690517 for at least six weeks, while continuing other indicated treatments like ACE inhibitors or ARBs. In the second part, participants are randomly assigned to take either BI 690517 tablets or placebo tablets once daily alongside empagliflozin for the rest of the study. The placebo tablets look like BI 690517 but contain no active medicine. Participants have regular visits to the study site, about four times in the first six months, then every six months afterward. During these visits, doctors monitor kidney function, heart health, blood pressure, weight, and any side effects. Blood and urine samples are taken to track health changes. The main outcomes measured are the time until worsening kidney disease, hospitalization for heart failure, or cardiovascular death. The study ends when a certain number of these events have occurred.

Preeclampsia is a common and serious pregnancy complication characterized by high blood pressure that can affect both mother and baby, leading to severe outcomes including neurological problems and reduced blood flow to the placenta. It contributes significantly to maternal and perinatal deaths, particularly in Mexico where it accounts for around 14% of maternal mortality. This study explores how disruptions in the autonomic nervous system, especially involving the vagus nerve that regulates inflammation and blood pressure, may influence preeclampsia development. The research evaluates the effects of vagal autonomic stimulation physiotherapy through trigger point release therapy as a complementary treatment for pregnant women with mild preeclampsia. Participants will be randomly assigned to either receive standard antihypertensive treatment combined with vagal stimulation therapy every two weeks or standard treatment with positional release therapy every two weeks as a control. Both therapies involve physical techniques applied by a therapist while the patient assumes specific positions, continuing from treatment start until about 4 to 5 weeks after delivery. Participants will be monitored closely with blood pressure and heart rate measurements taken every two weeks from baseline until 4 to 5 weeks after obstetric resolution. The study will also include personalized antihypertensive management and thorough assessments to evaluate the therapy's impact on hemodynamic control. The trial aims to offer a non-invasive, drug-free approach that may improve maternal and fetal health outcomes and reduce reliance on medication during pregnancy.